

1. *Brief Report: Inhibition of miR-145 Enhances Reprogramming of Human Dermal Fibroblasts to Induced Pluripotent Stem Cells.* Barta T, Peskova L, Collin J, **Montaner D**, Neganova I, et al. Stem cells (Dayton, Ohio). 2016; 34(1):246-51.
2. *Family-based genome-wide association study in Patagonia confirms the association of the DMD locus and cleft lip and palate.* Fonseca RF, de Carvalho FM, Poletta FA, **Montaner D**, Dopazo J, et al. European journal of oral sciences. 2015;
3. *Babelomics 5.0: functional interpretation for new generations of genomic data.* Alonso R, Salavert F, Garcia-Garcia F, Carbonell-Caballero J, Bleda M, et al. Nucleic acids research. 2015; 43(W1):W117-21.
4. *Therapeutic targets for olive pollen allergy defined by gene markers modulated by Ole e 1-derived peptides.* Calzada D, Aguerri M, Baos S, **Montaner D**, Mata M, et al. Molecular immunology. 2015; 64(2):252-61.
5. *A new overgrowth syndrome is due to mutations in RNF125.* Tenorio J, Mansilla A, Valencia M, Martínez-Glez V, Romanelli V, et al. Human mutation. 2014; 35(12):1436-41.
6. *Understanding disease mechanisms with models of signaling pathway activities.* Sebastian-Leon P, Vidal E, Minguez P, Conesa A, Tarazona S, et al. BMC systems biology. 2014; 8:121.
7. *A novel locus for a hereditary recurrent neuropathy on chromosome 21q21.* Calpena E, Martínez-Rubio D, Arpa J, García-Peñas JJ, **Montaner D**, et al. Neuromuscular disorders : NMD. 2014; 24(8):660-5.
8. *Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma.* Tadeo I, Piqueras M, **Montaner D**, Villamón E, Berbegall AP, et al. Pediatric research. 2014; 75(2):302-14.
9. *Pathway network inference from gene expression data.* Ponzoni I, Nueda M, Tarazona S, Götz S, **Montaner D**, et al. BMC systems biology. 2014; 8 Suppl 2:S7.
10. *Differential gene-expression analysis defines a molecular pattern related to olive pollen allergy.* Aguerri M, Calzada D, **Montaner D**, Mata M, Florido F, et al. Journal of biological regulators and homeostatic agents. 2013; 27(2):337-50.
11. *Defining the genomic signature of totipotency and pluripotency during early human development.* Galan A, Diaz-Gimeno P, Poo ME, Valbuena D, Sanchez E, et al. PloS one. 2013; 8(4):e62135.
12. *Four new loci associations discovered by pathway-based and network analyses of the genome-wide variability profile of Hirschsprung's disease.* Fernández RM, Bleda M, Núñez-Torres R, Medina I, Luzón-Toro B, et al. Orphanet journal of rare diseases. 2012; 7:103.
13. *The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells.* Koziol A, Gonzalo P, Mota A, Pollán Á, Lorenzo C, et al. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2012; 26(11):4481-94.
14. *Extensive translational remodeling during ER stress response in mammalian*

- cells. Ventoso I, Kochetov A, **Montaner D**, Dopazo J, Santoyo J. PLoS one. 2012; 7(5):e35915.
15. *Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells.* Yung S, Ledran M, Moreno-Gimeno I, Conesa A, **Montaner D**, et al. Human molecular genetics. 2011; 20(24):4932-46.
16. *Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice.* Prieur X, Mok CY, Velagapudi VR, Núñez V, Fuentes L, et al. Diabetes. 2011; 60(3):797-809.
17. *Functional genomics of 5- to 8-cell stage human embryos by blastomere single-cell cDNA analysis.* Galán A, **Montaner D**, Póo ME, Valbuena D, Ruiz V, et al. PLoS one. 2010; 5(10):e13615.
18. *The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.* Shi L, Campbell G, Jones WD, Campagne F, Wen Z, et al. Nature biotechnology. 2010; 28(8):827-38. NIHMSID: NIHMS235927
19. *Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling.* Medina I, Carbonell J, Pulido L, Madeira SC, Goetz S, et al. Nucleic acids research. 2010; 38(Web Server issue):W210-3.
20. *Multidimensional gene set analysis of genomic data.* **Montaner D**, Dopazo J. PLoS one. 2010; 5(4):e10348.
21. *Hypoxia promotes efficient differentiation of human embryonic stem cells to functional endothelium.* Prado-Lopez S, Conesa A, Armiñán A, Martínez-Losa M, Escobedo-Lucea C, et al. Stem cells (Dayton, Ohio). 2010; 28(3):407-18.
22. *Initial genomics of the human nucleolus.* Németh A, Conesa A, Santoyo-Lopez J, Medina I, **Montaner D**, et al. PLoS genetics. 2010; 6(3):e1000889.
23. *FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status.* Moreno-Manzano V, Rodríguez-Jiménez FJ, Aceña-Bonilla JL, Fustero-Lardies S, Erceg S, et al. The Journal of biological chemistry. 2010; 285(2):1333-42.
24. *DNA methylation epigenotypes in breast cancer molecular subtypes.* Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, et al. Breast cancer research : BCR. 2010; 12(5):R77.
25. *Parallel changes in gene expression in peripheral blood mononuclear cells and the brain after maternal separation in the mouse.* van Heerden JH, Conesa A, Stein DJ, **Montaner D**, Russell V, et al. BMC research notes. 2009; 2:195.
26. *SNOW, a web-based tool for the statistical analysis of protein-protein interaction networks.* Minguez P, Götz S, **Montaner D**, Al-Shahrour F, Dopazo J. Nucleic acids research. 2009; 37(Web Server issue):W109-14.
27. *Gene set-based analysis of polymorphisms: finding pathways or biological*

- processes associated to traits in genome-wide association studies.* Medina I, **Montaner D**, Bonifaci N, Pujana MA, Carbonell J, et al. Nucleic acids research. 2009; 37(Web Server issue):W340-4.
28. *Gene set internal coherence in the context of functional profiling.* **Montaner D**, Minguez P, Al-Shahrour F, Dopazo J. BMC genomics. 2009; 10:197.
 29. *Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia.* Lewintre EJ, Martín CR, Ballesteros CG, **Montaner D**, Rivera RF, et al. Haematologica. 2009; 94(2):280-4.
 30. *Analysis of chronic lymphocytic leukemia transcriptomic profile: differences between molecular subgroups.* Jantus Lewintre E, Reinoso Martín C, **Montaner D**, Marín M, José Terol M, et al. Leukemia & lymphoma. 2009; 50(1):68-79.
 31. *Direct functional assessment of the composite phenotype through multivariate projection strategies.* Conesa A, Bro R, García-García F, Prats JM, Götz S, et al. Genomics. 2008; 92(6):373-83.
 32. *GEPAS, a web-based tool for microarray data analysis and interpretation.* Tárraga J, Medina I, Carbonell J, Huerta-Cepas J, Minguez P, et al. Nucleic acids research. 2008; 36(Web Server issue):W308-14.
 33. *Babelomics: advanced functional profiling of transcriptomics, proteomics and genomics experiments.* Al-Shahrour F, Carbonell J, Minguez P, Goetz S, Conesa A, et al. Nucleic acids research. 2008; 36(Web Server issue):W341-6.
 34. *Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.* Montero-Conde C, Martín-Campos JM, Lerma E, Gimenez G, Martínez-Guitarte JL, et al. Oncogene. 2008; 27(11):1554-61.
 35. *CLEAR-test: combining inference for differential expression and variability in microarray data analysis.* Valls J, Grau M, Solé X, Hernández P, **Montaner D**, et al. Journal of biomedical informatics. 2008; 41(1):33-45.
 36. *Functional profiling of microarray experiments using text-mining derived bioentities.* Minguez P, Al-Shahrour F, **Montaner D**, Dopazo J. Bioinformatics (Oxford, England). 2007; 23(22):3098-9.
 37. *ISACGH: a web-based environment for the analysis of Array CGH and gene expression which includes functional profiling.* Conde L, **Montaner D**, Burguet-Castell J, Tárraga J, Medina I, et al. Nucleic acids research. 2007; 35(Web Server issue):W81-5.
 38. *FatiGO +: a functional profiling tool for genomic data. Integration of functional annotation, regulatory motifs and interaction data with microarray experiments.* Al-Shahrour F, Minguez P, Tárraga J, Medina I, Alloza E, et al. Nucleic acids research. 2007; 35(Web Server issue):W91-6.
 39. *Evidence for systems-level molecular mechanisms of tumorigenesis.* Hernández P, Huerta-Cepas J, **Montaner D**, Al-Shahrour F, Valls J, et al. BMC genomics. 2007; 8:185.
 40. *Functional profiling and gene expression analysis of chromosomal copy number alterations.* Conde L, **Montaner D**, Burguet-Castell J, Tárraga

- J, Al-Shahrour F, et al. *Bioinformatics*. 2007; 1(10):432-5.
41. *From genes to functional classes in the study of biological systems*. Al-Shahrour F, Arbiza L, Dopazo H, Huerta-Cepas J, Mínguez P, et al. *BMC bioinformatics*. 2007; 8:114.
 42. *Prophet, a web-based tool for class prediction using microarray data*. Medina I, **Montaner D**, Tárraga J, Dopazo J. *Bioinformatics (Oxford, England)*. 2007; 23(3):390-1.
 43. *The detection, treatment and control of high blood pressure in older British adults: cross-sectional findings from the British Women's Heart and Health Study and the British Regional Heart Study*. Patel R, Lawlor DA, Whincup P, **Montaner D**, Papacosta O, et al. *Journal of human hypertension*. 2006; 20(10):733-41.
 44. *BABELOMICS: a systems biology perspective in the functional annotation of genome-scale experiments*. Al-Shahrour F, Mínguez P, Tárraga J, **Montaner D**, Alloza E, et al. *Nucleic acids research*. 2006; 34(Web Server issue):W472-6.
 45. *Next station in microarray data analysis: GEPAS*. **Montaner D**, Tárraga J, Huerta-Cepas J, Burguet J, Vaquerizas JM, et al. *Nucleic acids research*. 2006; 34(Web Server issue):W486-91.
 46. *Self-reported smoking cessation interventions were not associated with quitting in older women*. Schroeder K, Lawlor DA, **Montaner D**, Ebrahim S. *Journal of clinical epidemiology*. 2006; 59(6):622-8.
 47. *Selective pressures at a codon-level predict deleterious mutations in human disease genes*. Arbiza L, Duchi S, **Montaner D**, Burguet J, Pantoja-Uceda D, et al. *Journal of molecular biology*. 2006; 358(5):1390-404.
 48. *How acceptable are innovative health-care technologies? A survey of public beliefs and attitudes in England and Wales*. Calnan M, **Montaner D**, Horne R. *Social science & medicine (1982)*. 2005; 60(9):1937-48.
 49. *Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women*. Emberson JR, Whincup PH, Lawlor DA, **Montaner D**, Ebrahim S. *Heart (British Cardiac Society)*. 2005; 91(4):451-5.
 50. *Clustering of risk factors and social class in childhood and adulthood in British women's heart and health study: cross sectional analysis*. Ebrahim S, **Montaner D**, Lawlor DA. *BMJ (Clinical research ed.)*. 2004; 328(7444):861.